Compare LRN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | IMVT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.3B |
| IPO Year | 2007 | N/A |
| Metric | LRN | IMVT |
|---|---|---|
| Price | $66.26 | $26.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $113.25 | $27.75 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 01-27-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.30 | N/A |
| EPS | ★ 6.34 | N/A |
| Revenue | ★ $2,475,117,000.00 | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $10.37 | ★ N/A |
| Revenue Growth | ★ 17.25 | N/A |
| 52 Week Low | $60.62 | $12.72 |
| 52 Week High | $171.17 | $28.00 |
| Indicator | LRN | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 66.56 |
| Support Level | $61.07 | $25.84 |
| Resistance Level | $67.75 | $27.69 |
| Average True Range (ATR) | 2.03 | 1.39 |
| MACD | 2.41 | 0.26 |
| Stochastic Oscillator | 77.00 | 85.42 |
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.